Lynx1 Capital Management LP — 13F holdings

Lynx1 Capital Management LP reported 27 holdings worth $866M in its 13F filing for Q2 2026, filed August 13, 2026.

Largest positions

1. GHRS GH RESEARCH PLC — $357M (41.2%)
2. CGEM CULLINAN THERAPEUTICS INC — $163M (18.9%)
3. STOK Stoke Therapeutics Inc — $132M (15.3%)
4. AGIO Agios Pharmaceuticals Inc — $127M (14.6%)
5. CCCC C4 THERAPEUTICS INC — $34.2M (4.0%)
6. KRRO KORRO BIO INC — $20.3M (2.3%)
7. TCRX TSCAN THERAPEUTICS INC — $7.86M (0.9%)
8. DTIL PRECISION BIOSCIENCES INC — $7.47M (0.9%)
9. NEUP NEUPHORIA THERAPEUTICS INC — $3.83M (0.4%)
10. PASG PASSAGE BIO INC — $3.29M (0.4%)